Clinical Trial Update: Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial of sargramostim in patients receiving myelosuppressive induction chemotherapy for acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• sargramostim (sargramostim)

Snippet

Sponsor: Sanofi | Conditions: Acute Myeloid Leukemia NOS | Phase 2 | Status: WITHDRAWN